骨硬化蛋白在血管钙化及动脉粥样硬化性心脏病中的作用机制研究进展  

Research progress of mechanisms of sclerostin in vascular calcification and atherosclerotic heart disease

作　　者：杨浩[1] 徐静 李樊丹 杜孝亮 吕湛[1] YANG Hao;XU Jing;LI Fandan;DU Xiaoliang;LÜ Zhan(Department of Cardiology,Affiliated Hospital of North Sichuan Medical College,Nanchong,Sichuan 637000,P.R.China)

机构地区：[1]川北医学院附属医院心血管内科,四川南充637000

出　　处：《华西医学》2024年第12期1953-1957,共5页West China Medical Journal

基　　金：川北医学院校级科研发展基金项目(2023JC012)。

摘　　要：骨硬化蛋白作为骨源性分泌型糖蛋白,是Wnt信号通路的抑制因子。近来,使用骨硬化蛋白抑制剂治疗骨质疏松过程中出现了心血管不良事件,这引起人们对骨硬化蛋白与动脉粥样硬化性心脏病相关性的关注。骨硬化蛋白在动脉粥样硬化性心脏病中的作用是有害还是有益尚不明确。该文对骨硬化蛋白在血管钙化及动脉粥样硬化性心脏病中的作用机制研究进展进行了综述,主要探讨了骨硬化蛋白与血管钙化的关系、其浓度改变对动脉粥样硬化性心脏病的影响以及骨硬化蛋白抑制剂对心血管事件的影响。Sclerostin,as a bone-derived secreted glycoprotein,is a suppressor of Wnt signaling pathway.Recently,adverse cardiovascular events in the treatment of osteoporosis with sclerostin inhibitors have raised concerns about the association of sclerostin with atherosclerotic heart disease.Whether the role of sclerostin in atherosclerotic heart disease is harmful or beneficial is not clear.This article reviews the progress of the mechanisms of sclerostin in vascular calcification and atherosclerotic heart disease,focusing on the relationship between sclerostin and vascular calcification,the impact of its concentration changes on atherosclerotic heart disease,and the effect of sclerostin inhibitor on cardiovascular events.

关 键 词：骨硬化蛋白 血管钙化 动脉粥样硬化 心血管疾病 

分 类 号：R54[医药卫生—心血管疾病]